Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Meet us at Facebook

facebook   Follow us on Twitter

   Follow us on LinkedIn 

Vaccibody

Clinical stage biopharmaceutical company

Vaccibody is a clinical stage biopharmaceutical company that has developed its own proprietary vaccine technology platform for the treatment of cancer, pre-cancerous diseases and infectious diseases. Due to the modular structure of the vaccine, it easy to modify, making it uniquely suited for creating individualised vaccines, in addition to off the shelf vaccines, optimised to each type of disease. The company is currently pursuing two clinical research programs: VB10.16, a therapeutic HPV16 vaccine and VB10.NEO a cancer neoantigen vaccine specifically tailored to each patient.

There are significant opportunities for Vaccibody if the technology works. The biggest potential clearly is in treatment of cancers, but it also has potential as treatment of precancerous malignancies and infectious diseases.

The key risks with Vaccibody are related to clinical risk and the development of its candidates.

NOKm 2018 2019e 2020e
Sales 11 8 8
Sales growth (%) 12,4 -27,1 0
EBITDA -62 -90 -101
EBITDA margin (%) -565 -1125 -1262,5
EBIT adj -62 -90 -101
EBIT adj margin (%) -565,6 -1126 -1263,5
Pretax profit -61 -89 -100
EPS rep -1,26 -1,65 -1,85
EPS growth (%) 90,3 -30,2 -12,3
EPS adj -1,26 -1,65 -1,85
DPS 0 0 0
EV/EBITDA (x) N/A N/A N/A
EV/EBIT adj (x) N/A N/A N/A
P/E (x) N/A N/A N/A
P/E adj (x) N/A N/A N/A
EV/sales (x) N/A N/A N/A
FCF yield (%) N/A N/A N/A
Dividend yield (%) N/A N/A N/A
Net IB debt/EBITDA 2,3 3 1,7
NOKm 2018 2019e 2020e
Sales 11 8 8
COGS 0 0 0
Gross profit 11 8 8
Other operating items -73 -98 -109
EBITDA -62 -90 -101
Depreciation on tangibles 0 0 0
Depreciation on intangibles 0 0 0
EBITA -62 -90 -101
Goodwill impairment charges 0 0 0
Other impairment and amortisation 0 0 0
EBIT -62 -90 -101
Other financial items 0 0 0
Net financial items 1 1 1
Associated income 0 0 0
Other EO items 0 0 0
Pretax profit -61 -89 -100
Tax 0 0 0
Net profit -61 -89 -100
Minority interest 0 0 0
Net profit discontinued 0 0 0
Net profit to shareholders -61 -89 -100
EPS -1,26 -1,65 -1,85
EPS Adj -1,26 -1,65 -1,85
Total extraordinary items after tax 0 0 0
Tax rate (%) 0 0 0
Gross margin (%) 100 100 100
EBITDA margin (%) -565 -1125 -1262,5
EBITA margin (%) -565,6 -1126 -1263,5
EBIT margin (%) -565,6 -1126 -1263,5
Pretax margin (%) -558,3 -1116 -1253,5
Net margin (%) -558,3 -1116 -1253,5
Growth rates Y/Y 2018 2019 2020
Sales growth (%) 12,4 -27,1 0
EBITDA growth (%) -82,9 -45,2 -12,2
EBIT growth (%) -82,7 -45,2 -12,2
Net profit growth (%) -95,3 -45,7 -12,3
EPS growth (%) 90,3 -30,2 -12,3
Profitability 2018 2019 2020
ROE (%) -39,6 -42,9 -44,9
ROE Adj (%) -39,6 -42,9 -44,9
ROCE (%) -40,2 -43,3 -45,3
ROCE Adj(%) -40,2 -43,3 -45,3
ROIC (%) 2004,7 1262,9 1401,4
ROIC Adj (%) 2004,7 1262,9 1401,4
Adj earnings numbers 2018 2019 2020
EBITDA Adj -62 -90 -101
EBITDA Adj margin (%) -565 -1125 -1262,5
EBITA Adj -62 -90 -101
EBITA Adj margin (%) -565,6 -1126 -1263,5
EBIT Adj -62 -90 -101
EBIT Adj margin (%) -565,6 -1126 -1263,5
Pretax profit Adj -61 -89 -100
Net profit Adj -61 -89 -100
Net profit to shareholders Adj -61 -89 -100
Net Adj margin (%) -558,3 -1116 -1253,5
NOKm 2018 2019e 2020e
EBITDA -62 -90 -101
Net financial items 1 1 1
Paid tax 0 0 0
Non-cash items -1 0 0
Cash flow before change in WC -62 -89 -100
Change in WC 4 0 0
Operating cash flow -3 0 0
CAPEX tangible fixed assets 1 0 0
CAPEX intangible fixed assets 0 0 0
Acquisitions and disposals 0 0 0
Free cash flow -1 0 0
Dividend paid 0 0 0
Share issues and buybacks 0 220 0
Other non cash items -25 -89 -100
Decrease in net IB debt -26 131 -100
Balance Sheet (NOKm) 2018 2019 2020
Goodwill 0 0 0
Indefinite intangible assets 0 0 0
Definite intangible assets 0 0 0
Tangible fixed assets 0 0 0
Other fixed assets 0 0 0
Fixed assets 0 0 0
Inventories 0 0 0
Receivables 0 0 0
Other current assets 10 10 10
Cash and liquid assets 144 274 174
Total assets 154 285 185
Shareholders equity 143 273 173
Minority 0 0 0
Total equity 143 273 173
Long-term debt 0 0 0
Pension debt 0 0 0
Convertible debt 0 0 0
Deferred tax 0 0 0
Other long-term liabilities 0 0 0
Short-term debt 0 0 0
Accounts payable 7 7 7
Other current liabilities 4 4 4
Total liabilities and equity 83 179 154
Net IB debt -144 -274 -174
Net IB debt excl. pension debt -144 -274 -174
Capital invested -7 -7 -7
Working capital -7 -7 -7
EV breakdown 2018 2019 2020
Market cap. diluted (m) N/A N/A N/A
Net IB debt Adj -144 -274 -174
Market value of minority 0 0 0
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity 0 0 0
EV N/A N/A N/A
Capital efficiency (%) 2018 2019 2020
Total assets turnover (%) 6,6 3,6 3,4
Capital invested turnover (%) -354,5 -112,2 -110,9
Capital employed turnover (%) 7,1 3,8 3,6
Inventories / sales (%) 0 0 0
Customer advances / sales (%) 0 0 0
Payables / sales (%) 47,9 93,4 93,4
Working capital / sales (%) -47,9 -93,4 -93,4
Financial risk and debt service 2018 2019 2020
Net debt / equity (%) -100,7 -100,4 -100,7
Net debt / market cap (%) N/A N/A N/A
Equity ratio (%) 92,4 95,9 93,7
Net IB debt adj. / equity (%) -100,7 -100,4 -100,7
Current ratio (%) 1320,7 2443,4 1583,4
EBITDA / net interest (%) -7788,3 -11250 -12625
Net IB debt / EBITDA (%) 231,7 304,9 172,5
Interest cover (%) 7796 11260 12635
NOKm 2018 2019e 2020e
Shares outstanding adj. 48 54 54
Fully diluted shares Adj 48 54 54
EPS -1,26 -1,65 -1,85
Dividend per share Adj 0 0 0
EPS Adj -1,26 -1,65 -1,85
BVPS 2,94 5,04 3,19
BVPS Adj 2,94 5,04 3,19
Net IB debt / share -3 -5,1 -3,2
Share price N/A N/A N/A
Market cap. (m) N/A N/A N/A
Valuation 2018 2019 2020
P/E N/A N/A N/A
EV/sales N/A N/A N/A
EV/EBITDA N/A N/A N/A
EV/EBITA N/A N/A N/A
EV/EBIT N/A N/A N/A
Dividend yield (%) N/A N/A N/A
FCF yield (%) N/A N/A N/A
P/BVPS N/A N/A N/A
P/BVPS Adj N/A N/A N/A
P/E Adj N/A N/A N/A
EV/EBITDA Adj N/A N/A N/A
EV/EBITA Adj N/A N/A N/A
EV/EBIT Adj N/A N/A N/A
EV/cap. employed N/A N/A N/A
Investment ratios 2018 2019 2020
Capex / sales -10,9 0 0
Capex / depreciation -1955,7 0 0
Capex tangibles / tangible fixed assets -314,8 0 0
Capex intangibles / definite intangibles N/A N/A N/A
Depreciation on intangibles / definite intangibles N/A N/A N/A
Depreciation on tangibles / tangibles 16,1 26,8 36,5

Equity research

Read earlier research